Neuronetics (STIM) reported mixed Q2 2025 results, beating revenue estimates but posting a wider-than-expected loss, causing a 9% pre-market drop. Greenbrook clinics hit record revenue.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and positive EBITDA by 2025. Neuronetics to hold 57% ownership.
